Clinical Trial Update: Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating CHAM* for the treatment of diabetic foot ulcers sponsored by Osiris Therapeutics has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• CHAM*

Snippet

Sponsor: Osiris Therapeutics | Conditions: Chronic Diabetic Foot Ulcers | Phase 3 | Status: TERMINATED